MA53883A - Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations - Google Patents

Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations

Info

Publication number
MA53883A
MA53883A MA053883A MA53883A MA53883A MA 53883 A MA53883 A MA 53883A MA 053883 A MA053883 A MA 053883A MA 53883 A MA53883 A MA 53883A MA 53883 A MA53883 A MA 53883A
Authority
MA
Morocco
Prior art keywords
type
fusion proteins
receptor fusion
arm
arm type
Prior art date
Application number
MA053883A
Other languages
English (en)
Inventor
Asya Grinberg
Ravindra Kumar
Dianne S Sako
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MA53883A publication Critical patent/MA53883A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053883A 2015-04-06 2016-04-06 Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations MA53883A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562143579P 2015-04-06 2015-04-06
US201562259422P 2015-11-24 2015-11-24

Publications (1)

Publication Number Publication Date
MA53883A true MA53883A (fr) 2021-08-18

Family

ID=57015654

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053883A MA53883A (fr) 2015-04-06 2016-04-06 Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations

Country Status (21)

Country Link
US (3) US10358476B2 (fr)
EP (2) EP3865505A1 (fr)
JP (2) JP6810702B2 (fr)
KR (1) KR20170141215A (fr)
CN (3) CN113683708A (fr)
AU (2) AU2016246602B2 (fr)
CA (1) CA2981793A1 (fr)
CY (1) CY1124247T1 (fr)
DK (1) DK3280727T3 (fr)
ES (1) ES2864850T3 (fr)
HR (1) HRP20210411T1 (fr)
HU (1) HUE054180T2 (fr)
LT (1) LT3280727T (fr)
MA (1) MA53883A (fr)
MD (1) MD3280727T2 (fr)
PL (1) PL3280727T3 (fr)
PT (1) PT3280727T (fr)
RS (1) RS61728B1 (fr)
SI (1) SI3280727T1 (fr)
SM (1) SMT202100246T1 (fr)
WO (1) WO2016164501A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
HK1250373A1 (zh) 2015-04-06 2018-12-14 Acceleron Pharma Inc. Alk7:actriib异多聚体和其用途
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
MD3280727T2 (ro) 2015-04-06 2021-06-30 Acceleron Pharma Inc Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora
WO2017024171A1 (fr) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Procédés de traitement de syndrome myéloprolifératif
EP3439686A4 (fr) * 2016-04-06 2019-10-09 Acceleron Pharma Inc. Polypeptides bmprii et leurs utilisations
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
RU2748278C2 (ru) 2016-07-15 2021-05-21 Акселерон Фарма Инк. Композиции и способы лечения легочной гипертензии
JP7280182B2 (ja) 2016-10-05 2023-05-23 アクセルロン ファーマ インコーポレイテッド バリアントＡｃｔＲＩＩＢタンパク質およびその使用
US10934532B2 (en) 2016-10-05 2021-03-02 Acceleron Pharma Inc. ALK4.ActRIIB heteromultimers
CA3039545A1 (fr) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Heteromultimeres de recepteurs de type i et de type ii de la superfamille des tgf-beta et leurs utilisations
WO2018089715A1 (fr) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Variants de type iia du récepteur de l'activine et leurs méthodes d'utilisation
AU2018214979A1 (en) * 2017-02-01 2019-08-15 Acceleron Pharma Inc. TGFβ and actrii antagonists for use in increasing immune activity
CN110785431B (zh) * 2017-05-04 2024-05-07 阿塞勒隆制药公司 TGF-β受体II型融合蛋白及其用途
KR20250059538A (ko) 2017-11-09 2025-05-02 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
EP3735418A4 (fr) * 2018-01-03 2021-11-10 Acceleron Pharma Inc. Protéines de fusion de co-recepteur à bras unique et utilisations associées
JP7510875B2 (ja) 2018-01-12 2024-07-04 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
WO2019157342A1 (fr) * 2018-02-09 2019-08-15 Acceleron Pharma Inc. Procédés de traitement d'ossification hétérotopique
BR112020017382A2 (pt) 2018-03-09 2021-01-26 Agenus Inc. anticorpos anti-cd73 e métodos de uso dos mesmos
AU2019262139A1 (en) * 2018-05-03 2020-11-26 Acceleron Pharma Inc. Multispecific binders of TGFβ-superfamily ligands and uses thereof
KR20250133994A (ko) 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
SG11202101996QA (en) * 2018-08-28 2021-03-30 Immunotech Biopharm Co Ltd Improved therapeutic t cell
EP3999527A4 (fr) * 2019-07-18 2024-04-17 Memorial Sloan Kettering Cancer Center Procédés et compositions pour cibler la signalisation du tgf-beta dans des lymphocytes t auxiliaires cd4+ pour immunothérapie anticancéreuse
US20230190875A1 (en) * 2019-12-10 2023-06-22 Acceleron Pharma Inc. Single-arm actriia and actriib heteromultimers and methods for treating pulmonary hypertension
CA3171638A1 (fr) * 2020-03-13 2021-09-16 Acceleron Pharma Inc. Heteromultimeres actriia et actriib a bras unique et methodes de traitement de maladies ou de pathologies renales
KR20230004515A (ko) 2020-03-20 2023-01-06 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법
EP4121088A4 (fr) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Procédés d'utilisation de variants de récepteur de l'activine de type iib
MX2022016243A (es) * 2020-06-17 2023-03-08 Acceleron Pharma Inc Antagonistas de actrii-alk4 y métodos para el tratamiento contra insuficiencia cardíaca.
CN112190694B (zh) * 2020-09-17 2023-11-10 南通大学 细胞因子活化素c在治疗神经病理性疼痛方面的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382562D1 (de) 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE352638T1 (de) 1995-04-11 2007-02-15 Gen Hospital Corp REVERSE ßTWO-HYBRIDß-SYSTEME
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP1147413B1 (fr) 1999-01-21 2006-04-05 Metamorphix, Inc. Inhibiteurs de facteurs de differenciation de la croissance et leurs utilisations
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2005028517A2 (fr) * 2003-05-09 2005-03-31 The General Hospital Corporation PROTEINES DE FUSION SOLUBLES DU RECEPTEUR TGF- ss DE TYPE III
US7820620B2 (en) 2003-09-15 2010-10-26 Research Development Foundation Cripto antagonism of activin and TGF-b signaling
JP2007531513A (ja) * 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
ME00380B (fr) 2005-11-23 2011-10-10 Acceleron Pharma Inc Antagonistes de l'activine-actriia et utilisations pour activer la croissance osseuse
EP2035456A1 (fr) 2006-06-22 2009-03-18 Novo Nordisk A/S Production d'anticorps bispécifiques
WO2008057461A2 (fr) * 2006-11-02 2008-05-15 Acceleron Pharma, Inc. Récepteur alk1 et antagonistes de ligands et utilisations de ceux-ci
US9526759B2 (en) * 2007-02-01 2016-12-27 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
US8318135B2 (en) 2007-03-19 2012-11-27 National Research Council Of Canada Antagonist of ligands and uses thereof
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
JP5719766B2 (ja) * 2008-05-02 2015-05-20 アクセルロン ファーマ， インコーポレイテッド 血管新生および周皮細胞組成物を調節するための方法および組成物
CN107252486B (zh) 2008-06-26 2021-10-22 阿塞勒隆制药公司 激活素-actrii的拮抗剂及在提高红细胞水平中的用途
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CA2737271C (fr) 2008-09-17 2020-06-23 National Research Council Of Canada Agents de liaison hetero-multivalents pour des membres de la superfamille des tgf.beta.
KR20170105124A (ko) * 2008-11-26 2017-09-18 암젠 인크 액티빈 ｉｉｂ 수용체 폴리펩타이드의 변이체 및 이의 용도
JP5755635B2 (ja) 2009-03-30 2015-07-29 アクセルロン ファーマ， インコーポレイテッド Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用
JP2012529294A (ja) 2009-06-12 2012-11-22 アクセルロン ファーマ， インコーポレイテッド 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
WO2011034605A2 (fr) 2009-09-16 2011-03-24 Genentech, Inc. Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations
FR2951408B1 (fr) 2009-10-15 2012-01-13 Renault Sa Cadre moteur pour moteur electrique de vehicule automobile
WO2011056497A1 (fr) 2009-10-26 2011-05-12 Genentech, Inc. Compositions de récepteur de l'activine de type iib et leurs méthodes d'utilisation
US20110129469A1 (en) 2009-11-03 2011-06-02 Acceleron Pharma Inc. Methods for treating fatty liver disease
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
EP3299388A1 (fr) 2012-03-28 2018-03-28 The Board of Regents of The University of Texas System Fusions du récepteur de tgf de type ii-type iii
CN105658672A (zh) * 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
WO2016090035A2 (fr) 2014-12-02 2016-06-09 La Jolla Institute For Allergy And Immunology Modulateurs de l'activine et procédés de modulation de réponses immunitaires et de cellules t auxiliaires folliculaires
WO2016154601A1 (fr) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Protéines de fusion associées à la follistatine et leurs utilisations
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
HK1250373A1 (zh) 2015-04-06 2018-12-14 Acceleron Pharma Inc. Alk7:actriib异多聚体和其用途
MD3280727T2 (ro) 2015-04-06 2021-06-30 Acceleron Pharma Inc Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora
DK3286206T3 (da) 2015-04-22 2021-05-03 Biogen Ma Inc Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme
WO2016205370A1 (fr) 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Méthodes d'utilisation de protéines à base du récepteur iib de l'activine
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
US20200071382A1 (en) 2016-07-07 2020-03-05 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
US20180008672A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
US10934532B2 (en) 2016-10-05 2021-03-02 Acceleron Pharma Inc. ALK4.ActRIIB heteromultimers
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة

Also Published As

Publication number Publication date
US20220315642A1 (en) 2022-10-06
CN107849114B (zh) 2021-08-20
LT3280727T (lt) 2021-04-12
CN107849114A (zh) 2018-03-27
US20160289298A1 (en) 2016-10-06
EP3865505A1 (fr) 2021-08-18
US10358476B2 (en) 2019-07-23
EP3280727B1 (fr) 2021-02-17
US12338273B2 (en) 2025-06-24
CN113683709A (zh) 2021-11-23
US11208460B2 (en) 2021-12-28
JP6810702B2 (ja) 2021-01-06
WO2016164501A1 (fr) 2016-10-13
PL3280727T3 (pl) 2021-07-19
SMT202100246T1 (it) 2021-05-07
KR20170141215A (ko) 2017-12-22
ES2864850T3 (es) 2021-10-14
CA2981793A1 (fr) 2016-10-13
AU2021200906A1 (en) 2021-03-04
HUE054180T2 (hu) 2021-08-30
US20200055920A1 (en) 2020-02-20
HK1252958A1 (zh) 2019-06-06
JP2021054839A (ja) 2021-04-08
JP7203807B2 (ja) 2023-01-13
HRP20210411T1 (hr) 2021-04-30
AU2016246602A1 (en) 2017-10-26
RS61728B1 (sr) 2021-05-31
CY1124247T1 (el) 2022-07-22
EP3280727A1 (fr) 2018-02-14
DK3280727T3 (da) 2021-03-15
PT3280727T (pt) 2021-04-23
CN113683708A (zh) 2021-11-23
JP2018517664A (ja) 2018-07-05
SI3280727T1 (sl) 2021-07-30
AU2021200906B2 (en) 2023-04-06
AU2016246602B2 (en) 2020-11-19
EP3280727A4 (fr) 2019-02-13
MD3280727T2 (ro) 2021-06-30

Similar Documents

Publication Publication Date Title
MA53883A (fr) Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
FR25C1020I1 (fr) Anticorps thérapeutiques et leurs utilisations
MA44986A (fr) Protéines de fusion gdf15 et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
EP3490565A4 (fr) Modulateurs de récepteurs de chimiokine et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
EP3383904A4 (fr) Anticorps ctla-4 et leurs utilisations
EP3377102C0 (fr) Anticorps anti-pd-1 et leurs utilisations thérapeutiques
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
MA43552A (fr) Protéines immunomodulatrices à variants de cd80 et leurs utilisations
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
MA54328A (fr) Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
EP3352776A4 (fr) Répresseurs htt et leurs utilisations
EP3710484A4 (fr) Anticorps de liaison à ctla-4 et leurs utilisations
MA43308A (fr) Molécules d'anticorps se liant à april et leurs utilisations
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3325010A4 (fr) Anticorps anti-facteur de coagulation xia et leurs utilisations
EP3347021A4 (fr) Cyano-thiénotriazoloazépines et leurs utilisations